Furosemide & Digoxin Interaction

Furosemide and digoxin are frequently co-prescribed in heart failure management, but the combination carries a major interaction risk related to furosemide-induced electrolyte depletion ^[1][2]. Furosemide is a loop diuretic that causes significant potassium, magnesium, and calcium losses, and hypokalemia dramatically increases the risk of digoxin toxicity — including potentially fatal cardiac arrhythmias ^[1][2][3].

Digoxin has a narrow therapeutic index (therapeutic range 0.5-2.0 ng/mL, toxicity common above 2.0 ng/mL), and its cardiac effects are highly sensitive to electrolyte balance ^[2]. Hypokalemia enhances digoxin binding to the Na+/K+-ATPase pump and increases myocardial sensitivity to digoxin, meaning that digoxin toxicity can occur at normal digoxin serum levels when potassium is low ^[2][3].

Despite the interaction, the combination remains a cornerstone of heart failure management when used with appropriate electrolyte monitoring and potassium supplementation or potassium-sparing strategies ^[3][4].

Digoxin inhibits the Na+/K+-ATPase in cardiac myocytes, increasing intracellular sodium and (via the Na+/Ca2+ exchanger) intracellular calcium, which enhances cardiac contractility (positive inotropic effect) ^[2]. The Na+/K+-ATPase is the same pump that digoxin competes with for potassium binding. When extracellular potassium is low (hypokalemia), there is less competition for digoxin at the Na+/K+-ATPase binding site, effectively increasing digoxin binding and potentiating its effects ^[2][3].

Furosemide blocks the Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, causing natriuresis, kaliuresis, and loss of magnesium and calcium ^[1]. The resulting hypokalemia (and hypomagnesemia) increases myocardial irritability and susceptibility to digoxin-induced arrhythmias. Hypomagnesemia independently predisposes to digoxin toxicity and makes hypokalemia refractory to correction ^[1][3].

The interaction is purely pharmacodynamic — furosemide does not alter digoxin plasma levels. However, furosemide-induced reductions in renal blood flow and GFR (from volume depletion) can reduce digoxin clearance (digoxin is 60-80% renally excreted), indirectly increasing digoxin levels ^[1][2].

This interaction is major due to the potentially fatal consequences of digoxin toxicity in the setting of hypokalemia ^[2][3]. Digoxin toxicity manifests as cardiac arrhythmias (premature ventricular contractions, bigeminy, ventricular tachycardia, heart block), gastrointestinal symptoms (nausea, vomiting, anorexia), and neurologic symptoms (visual disturbances — classically yellow-green halos, confusion) ^[2].

A retrospective analysis found that hypokalemia was present in over 50% of digoxin toxicity cases, and that patients on concurrent loop diuretics had a 2-3 fold increased risk of digoxin-related hospitalization ^[3]. The risk is highest in elderly patients (reduced renal function), patients with acute illness (dehydration, vomiting, diarrhea), and those on high-dose furosemide ^[1][3].

Potassium levels must be maintained in the high-normal range (4.0-5.0 mEq/L) in patients on digoxin ^[2][3]. This is typically achieved through potassium supplementation (KCl 20-40 mEq/day) or co-administration of a potassium-sparing diuretic (spironolactone, which has independent mortality benefit in heart failure) ^[3][4]. Magnesium should also be maintained at normal levels (>2.0 mg/dL), as hypomagnesemia makes hypokalemia refractory to correction and independently increases digoxin toxicity risk ^[1][3].

Patients should be counseled to maintain adequate dietary potassium intake and to report symptoms of digoxin toxicity (nausea, visual changes, palpitations, confusion) or electrolyte depletion (muscle cramps, weakness, palpitations) immediately ^[2]. During acute illness with vomiting, diarrhea, or reduced oral intake, patients should contact their provider for guidance on digoxin and diuretic dosing ^[3].

Serum potassium at baseline, within 1 week of initiating furosemide (or dose changes), and at least every 1-3 months during stable therapy ^[1][3]. Serum magnesium at baseline and every 3-6 months. Digoxin serum level at baseline (target 0.5-0.9 ng/mL for heart failure), 1-2 weeks after dose changes, and every 6-12 months or whenever toxicity is suspected ^[2]. Renal function (BUN, creatinine) should be monitored regularly as both drugs affect and are affected by renal function ^[1][2]. ECG if digoxin toxicity is suspected (classic finding: ST segment scooping/Salvador Dali mustache, with arrhythmias in toxicity) ^[2][3].

Torsemide or bumetanide as alternative loop diuretics (similar electrolyte effects but torsemide may have less potassium wasting). Hydrochlorothiazide as an alternative diuretic (less potent, lower potassium wasting, but may be insufficient in advanced heart failure). Spironolactone or eplerenone combined with furosemide to counteract potassium loss while providing heart failure mortality benefit ^[4]. For heart failure: if digoxin is being used for rate control in atrial fibrillation, beta-blockers may allow digoxin discontinuation. SGLT2 inhibitors (empagliflozin, dapagliflozin) have mild diuretic effects with less electrolyte disruption ^[4].